183 related articles for article (PubMed ID: 15470907)
1. Imaging and peroxisome proliferator-activated receptor agonists: uncovering their role in atherosclerosis development.
Nissen SE
Clin Cardiol; 2004 Jul; 27(7 Suppl 4):IV17-20. PubMed ID: 15470907
[TBL] [Abstract][Full Text] [Related]
2. Will the potential of peroxisome proliferator-activated receptor agonists be realized in the clinical setting?
Blaschke F; Bruemmer D; Law RE
Clin Cardiol; 2004 Jul; 27(7 Suppl 4):IV3-10. PubMed ID: 15470905
[TBL] [Abstract][Full Text] [Related]
3. Peroxisome proliferator activated receptor gamma and its activation in the treatment of insulin resistance and atherosclerosis: issues and opportunities.
Beckman J; Raji A; Plutzky J
Curr Opin Cardiol; 2003 Nov; 18(6):479-85. PubMed ID: 14597889
[TBL] [Abstract][Full Text] [Related]
4. Peroxisome proliferator-activated receptor-gamma agonists in atherosclerosis: current evidence and future directions.
Roberts AW; Thomas A; Rees A; Evans M
Curr Opin Lipidol; 2003 Dec; 14(6):567-73. PubMed ID: 14624133
[TBL] [Abstract][Full Text] [Related]
5. Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice.
Li AC; Brown KK; Silvestre MJ; Willson TM; Palinski W; Glass CK
J Clin Invest; 2000 Aug; 106(4):523-31. PubMed ID: 10953027
[TBL] [Abstract][Full Text] [Related]
6. Angiographically silent atherosclerosis detected by intravascular ultrasound in patients with familial hypercholesterolemia and familial combined hyperlipidemia: correlation with high density lipoproteins.
Hausmann D; Johnson JA; Sudhir K; Mullen WL; Friedrich G; Fitzgerald PJ; Chou TM; Ports TA; Kane JP; Malloy MJ; Yock PG
J Am Coll Cardiol; 1996 Jun; 27(7):1562-70. PubMed ID: 8636537
[TBL] [Abstract][Full Text] [Related]
7. Peroxisome proliferator-activated receptor gamma: implications for cardiovascular disease.
Hsueh WA; Bruemmer D
Hypertension; 2004 Feb; 43(2):297-305. PubMed ID: 14732733
[TBL] [Abstract][Full Text] [Related]
8. The potential role of peroxisome proliferator-activated receptors on inflammation in type 2 diabetes mellitus and atherosclerosis.
Plutzky J
Am J Cardiol; 2003 Aug; 92(4A):34J-41J. PubMed ID: 12957325
[TBL] [Abstract][Full Text] [Related]
9. Thiazolidinediones, peroxisome proliferator-activated receptor gamma agonists, regulate endothelial cell growth and secretion of vasoactive peptides.
Fukunaga Y; Itoh H; Doi K; Tanaka T; Yamashita J; Chun TH; Inoue M; Masatsugu K; Sawada N; Saito T; Hosoda K; Kook H; Ueda M; Nakao K
Atherosclerosis; 2001 Sep; 158(1):113-9. PubMed ID: 11500181
[TBL] [Abstract][Full Text] [Related]
10. Peroxisome proliferator-activated receptor-gamma agonists for management and prevention of vascular disease in patients with and without diabetes mellitus.
Ríos-Vázquez R; Marzoa-Rivas R; Gil-Ortega I; Kaski JC
Am J Cardiovasc Drugs; 2006; 6(4):231-42. PubMed ID: 16913824
[TBL] [Abstract][Full Text] [Related]
11. What are the effects of peroxisome proliferator-activated receptor agonists on adiponectin, tumor necrosis factor-alpha, and other cytokines in insulin resistance?
Boyle PJ
Clin Cardiol; 2004 Jul; 27(7 Suppl 4):IV11-6. PubMed ID: 15470906
[TBL] [Abstract][Full Text] [Related]
12. PPARgamma and atherosclerosis.
Staels B
Curr Med Res Opin; 2005; 21 Suppl 1():S13-20. PubMed ID: 15811195
[TBL] [Abstract][Full Text] [Related]
13. The effects of rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, on markers of endothelial cell activation, C-reactive protein, and fibrinogen levels in non-diabetic coronary artery disease patients.
Sidhu JS; Cowan D; Kaski JC
J Am Coll Cardiol; 2003 Nov; 42(10):1757-63. PubMed ID: 14642684
[TBL] [Abstract][Full Text] [Related]
14. Regulation of macrophage gene expression by peroxisome-proliferator-activated receptor gamma: implications for cardiovascular disease.
Tontonoz P; Nagy L
Curr Opin Lipidol; 1999 Dec; 10(6):485-90. PubMed ID: 10680041
[TBL] [Abstract][Full Text] [Related]
15. Modulation of PPARgamma activity with pharmaceutical agents: treatment of insulin resistance and atherosclerosis.
Wang M; Tafuri S
J Cell Biochem; 2003 May; 89(1):38-47. PubMed ID: 12682906
[TBL] [Abstract][Full Text] [Related]
16. Antiinflammatory properties of PPARgamma agonists following ischemia.
Sundararajan S; Landreth GE
Drug News Perspect; 2004 May; 17(4):229-36. PubMed ID: 15334171
[TBL] [Abstract][Full Text] [Related]
17. Peroxisome proliferator-activated receptor agonists, hyperlipidaemia, and atherosclerosis.
Vosper H; Khoudoli GA; Graham TL; Palmer CN
Pharmacol Ther; 2002 Jul; 95(1):47-62. PubMed ID: 12163127
[TBL] [Abstract][Full Text] [Related]
18. Agonists of peroxisome proliferator-activated receptor gamma inhibit cell growth in malignant melanoma.
Mössner R; Schulz U; Krüger U; Middel P; Schinner S; Füzesi L; Neumann C; Reich K
J Invest Dermatol; 2002 Sep; 119(3):576-82. PubMed ID: 12230498
[TBL] [Abstract][Full Text] [Related]
19. Expression of peroxisome proliferator-activated receptor subtypes in human atherosclerosis.
Sueyoshi S; Yamada T; Niihasi M; Kusumi Y; Oinuma T; Esumi M; Tsuru K; Imai S; Nemoto N; Sakura I; Mitsumata M
Ann N Y Acad Sci; 2001 Dec; 947():429-32. PubMed ID: 11795308
[TBL] [Abstract][Full Text] [Related]
20. PPAR agonists in the treatment of atherosclerosis.
Francis GA; Annicotte JS; Auwerx J
Curr Opin Pharmacol; 2003 Apr; 3(2):186-91. PubMed ID: 12681242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
